Mrs. Kathleen W Hughes, LCSW Counselor Medicare: Accepting Medicare Assignments Practice Location: 1800 Lake Ave, Seaside Park, NJ 08752 Phone: 732-830-9044 |
News Archive
Abbott today announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a very low rate of major adverse cardiac events (MACE(1) rate of 2.0 percent) at 30 days.
In a recent Rutgers study, 38 percent of patients discharged from the emergency department had at least one drug interaction resulting from a newly prescribed medicine.
Researchers at the NYU Grossman School of Medicine have shown that a second dose of the Pfizer-BioNTech BNT162b2 vaccine may not offer any additional protection against coronavirus disease 2019 (COVID-19) over one dose among individuals previously infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Now, a new study published on the preprint server medRxiv* in June 2020 reports that viral RNA has been found to occur in HVAC (Heating, Ventilation, and AC) units in healthcare facilities. However, it is not clear if this represents a possible mechanism of viral transmission.
› Verified 5 days ago